Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 4 | 9 | 13 |
| 2005 | 9 | 13 | 22 |
| 2006 | 42 | 21 | 63 |
| 2007 | 44 | 33 | 77 |
| 2008 | 40 | 34 | 74 |
| 2009 | 60 | 30 | 90 |
| 2010 | 71 | 36 | 107 |
| 2011 | 80 | 42 | 122 |
| 2012 | 78 | 54 | 132 |
| 2013 | 90 | 46 | 136 |
| 2014 | 86 | 46 | 132 |
| 2015 | 95 | 45 | 140 |
| 2016 | 84 | 42 | 126 |
| 2017 | 92 | 54 | 146 |
| 2018 | 82 | 36 | 118 |
| 2019 | 80 | 51 | 131 |
| 2020 | 59 | 45 | 104 |
| 2021 | 68 | 49 | 117 |
| 2022 | 11 | 86 | 97 |
| 2023 | 8 | 90 | 98 |
| 2024 | 26 | 37 | 63 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Mol Cancer. 2024 Oct 30; 23(1):242.
-
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clin Cancer Res. 2024 Oct 15; 30(20):4572-4583.
-
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024 Oct 01; 109(10):3251-3260.
-
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. Cancer Med. 2024 Oct; 13(19):e70310.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Res Commun. 2024 Oct 01; 4(10):2621-2637.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
-
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11?+?17/18?mutations. Future Oncol. 2024; 20(27):1973-1982.
-
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767.
-
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271.